Expression of MAGE A1-6 and the clinical characteristics of papillary thyroid carcinoma

Anticancer Research

Volumn 33, Issue 4, 2013, Pages 1731-1736

  Lee, Hyoung Shin ^a   Kim, Sung Won ^a   Hong, Jong Chul ^b   Jung, Sang Bong ^c   Jeon, Chang Ho ^d   Park, Jong Wook ^e   Park, Sung Young ^f   Lee, Kang Dae ^a  

^a Kosin University College of Medicine   (South Korea)

^b Dong A University College of Medicine   (South Korea)

^c Department of Physical Therapy   (South Korea)

^d Catholic University of Daegu   (South Korea)

^e Keimyung University   (South Korea)

^f Chungju National University   (South Korea)

Author keywords

Melanoma associated antigen (MAGE); Papillary thyroid carcinoma; Reverse transcriptase polymerase chain reaction

Indexed keywords

MELANOMA ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; OUTCOME ASSESSMENT; PAPILLARY THYROID CANCER; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; THYROID CARCINOMA; THYROIDECTOMY; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA-SPECIFIC ANTIGENS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84876774669     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C and Guo GL: International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20: 525-531, 2009.
2. Kouniavsky G and Zeiger MA: The quest for diagnostic molecular markers for thyroid nodules with indeterminate or suspicious cytology. J Surg Oncol 105: 438-443, 2012.
3. Park MS, Park JW, Jeon CH, Lee KD and Chang HK: Expression of melanoma antigen-encoding genes (MAGE) by common primers for MAGE-A1 to-A6 in colorectal carcinomas among Koreans. J Korean Med Sci 17: 497-501, 2002.
4. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991. (Pubitemid 21917508)
5. Lee KD, Chang HK, Jo YK, Kim BS, Lee BH, Lee YW, Lee HK, Huh MH, Min YG and Spagnoli GC: Expression of the MAGE 3 gene product in squamous cell carcinomas of the head and neck. Anticancer Res 19: 5037-5042, 1999. (Pubitemid 30103320)
6. Inoue H, Mori M, Honda M, Li J, Shibuta K, Mimori K, Ueo H and Akiyoshi T: The expression of tumor-rejection antigen MAGE genes in human gastric carcinoma. Gastroenterology 109: 1522-1525, 1995.
7. Inoue H, Mori M, Li J, Mimori K, Honda M, Nakashima H, Mafune K, Tanaka Y and Akiyoshi T: Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer 63: 523-526, 1995.
8. Jheon S, Hyun DS, Lee SC, Yoon GS, Jeon CH, Park JW, Park CK, Jung MH, Lee KD and Chang HK: Lung cancer detection by a RT-nested PCR using MAGE A1-6 common primers. Lung Cancer 43: 29-37, 2004. (Pubitemid 38096289)
9. Russo V, Traversari C, Verrecchia A, Mottolese M, Natali PG and Bordignon C: Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer 64: 216-221, 1995.
10. Russo V, Dalerba P, Ricci A, Bonazzi C, Leone BE, Mangioni C, Allavena P, Bordignon C and Traversari C: MAGE, BAGE and GAGE gene expression in fresh epithelial ovarian carcinomas. Int J Cancer 67: 457-460, 1996.
11. Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K and Niho Y: High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology 24: 1437-1440, 1996. (Pubitemid 26399046)
12. Zammatteo N, Lockman L, Brasseur F, De Plaen E, Lurquin C, Lobert PE, Hamels S, Boon T and Remacle J: DNA microarray to monitor the expression of MAGE-A genes. Clin Chem 48: 25-34, 2002. (Pubitemid 34038119)
13. Park JW, Kwon TK, Kim IH, Sohn SS, Kim YS, Kim CI, Bae OS, Lee KS, Lee KD and Lee CS: A new strategy for the diagnosis of MAGE-expressing cancers. J Immunol Methods 266: 79-86, 2002. (Pubitemid 34804674)
14. Lee KD, Lee HH, Joo HB, Lee HS, Yu TH, Chang HK, Jeon CH and Park JW: Expression of MAGE A 1-6 mRNA in sputa of head and neck cancer patients-A preliminary report. Anticancer Res 26: 1513-1518, 2006.
15. Milkovic M, Sarcevic B and Glavan E: Expression of MAGE tumor-associated antigen in thyroid carcinomas. Endocr Pathol 17: 45-52, 2006. (Pubitemid 43997972)
16. Cheng S, Liu W, Mercado M, Ezzat S and Asa SL: Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer. Endocr Relat Cancer 16: 455-466, 2009.
17. Melo DH, Mamede RCM, Neder L, Saggioro FP, Figueiredo DLA, Araujo da Silva W Jr., Jungbluth AA and Zago MA: Expression of MAGE-A4 and MAGE-C1 tumor-associated antigen in benign and malignant thyroid diseases. Head Neck 33: 1426-1432, 2011.
18. Liu W, Cheng S, Asa SL and Ezzat S: The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 68: 8104, 2008.
19. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M and Schneider C: MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 103: 11160-11165, 2006. (Pubitemid 44156489)
20. Glazer CA, Smith IM, Bhan S, Sun W, Chang SS, Pattani KM, Westra W, Khan Z and Califano JA: The role of MAGEA2 in head and neck cancer. Arch Otolaryngol Head Neck Surg 137: 286, 2011.
21. Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL and Ezzat S: Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 67: 5461-5470, 2007. (Pubitemid 46997287)
22. Lee KD, Eura M, Ogi K, Nakano K, Chikamatus K, Masuyama K and Ishikawa T: Expression of the MAGE-1, -2, -3, -4, and -6 genes in non-squamous cell carcinoma lesions of the head and neck. Acta Otolaryngol 116: 633-639, 1996. (Pubitemid 26226392)
23. Kondo T, Ezzat S and Asa SL: Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292-306, 2006.